Full text is available at the source.
Abstract
The ACHIEVE-3 clinical trial evaluated the impact of oral glucagon-like peptide 1 receptor agonists on patients with type 2 diabetes.
- Patients reported positive treatment experiences with oral glucagon-like peptide 1 receptor agonists.
- Improvements in daily life were noted, alongside glycemic control and weight reduction.
- The study aimed to capture aspects of treatment outcomes beyond traditional clinical measures.
Simplified